A patient’s limb is amputated every 30 seconds.¹ That is just one factor contributing to the 537 million people affected by diabetes whom wound care clinicians are treating.² And in the US, these clinicians are caring for another 6.5 million patients suffering from chronic wounds also due to diabetes and other underlying conditions like cardiovascular disease.²

For diabetic foot ulcers, the annual treatment dollars spent cost tens of billions globally, and that overall cost per patient doubles when amputation is required.³ The cost to a patient is the most painful—not just financially. Wounds that fail to achieve 50% closure in four weeks are more vulnerable to infection, amputation, and even death.⁴

These cases can benefit from an advanced wound care modality like an amniotic allograft.⁴ Compared to standard-of-care treatment by itself, amniotic allografts increased the total wound closure for diabetic foot ulcers by nearly 400% in the first 6 weeks.³ This is why we continue to study and innovate our products based on strong clinical evidence.